[{"address1": "175 Innovation Boulevard", "city": "Wilmington", "state": "DE", "zip": "19805", "country": "United States", "phone": "302 467 1280", "website": "https://preludetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.", "fullTimeEmployees": 131, "companyOfficers": [{"maxAge": 1, "name": "Dr. Krishna  Vaddi D.V.M., Ph.D.", "age": 58, "title": "Founder, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 881092, "exercisedValue": 0, "unexercisedValue": 12515}, {"maxAge": 1, "name": "Mr. Bryant David Lim J.D.", "age": 53, "title": "CFO, Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 621017, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Aimee  Crombie Ph.D.", "title": "Senior VP and Head of Strategic Planning & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Madhu  Pudipeddi Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peggy A. Scherle Ph.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 868617, "exercisedValue": 0, "unexercisedValue": 436567}, {"maxAge": 1, "name": "Mr. Robert A. Doody Jr.", "title": "Senior Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michele  Porreca M.B.A.", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew P. Combs Ph.D.", "age": 57, "title": "Executive VP & Chief Chemistry Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 562461, "exercisedValue": 0, "unexercisedValue": 399432}, {"maxAge": 1, "name": "Mr. Naveen  Babbar Ph.D.", "title": "Senior Vice President of Translation Medicine", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wan-Jen  Hong M.D.", "age": 45, "title": "Senior Vice President of Clinical Development", "yearBorn": 1979, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.63, "open": 1.64, "dayLow": 1.6021, "dayHigh": 1.72, "regularMarketPreviousClose": 1.63, "regularMarketOpen": 1.64, "regularMarketDayLow": 1.6021, "regularMarketDayHigh": 1.72, "payoutRatio": 0.0, "beta": 1.056, "forwardPE": -1.4934498, "volume": 341410, "regularMarketVolume": 341410, "averageVolume": 1375980, "averageVolume10days": 318570, "averageDailyVolume10Day": 318570, "bid": 1.68, "ask": 1.74, "bidSize": 1, "askSize": 1, "marketCap": 107499616, "fiftyTwoWeekLow": 0.61, "fiftyTwoWeekHigh": 4.22, "allTimeHigh": 95.375, "allTimeLow": 0.61, "priceToSalesTrailing12Months": 10.238059, "fiftyDayAverage": 1.5405, "twoHundredDayAverage": 1.064655, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 103796656, "profitMargins": 0.0, "floatShares": 16354247, "sharesOutstanding": 50015011, "sharesShort": 995838, "sharesShortPriorMonth": 567052, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.015800001, "heldPercentInsiders": 0.09934, "heldPercentInstitutions": 0.54482, "shortRatio": 0.31, "shortPercentOfFloat": 0.0722, "impliedSharesOutstanding": 62865270, "bookValue": 0.769, "priceToBook": 2.2236671, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -111772000, "trailingEps": -1.47, "forwardEps": -1.145, "enterpriseToRevenue": 9.885, "enterpriseToEbitda": -0.87, "52WeekChange": 0.81919646, "SandP52WeekChange": 0.13613915, "quoteType": "EQUITY", "currentPrice": 1.71, "targetHighPrice": 5.0, "targetLowPrice": 3.0, "targetMeanPrice": 4.0, "targetMedianPrice": 4.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 54957000, "totalCashPerShare": 0.667, "ebitda": -119267000, "totalDebt": 17854000, "quickRatio": 3.021, "currentRatio": 3.207, "totalRevenue": 10500000, "debtToEquity": 30.502, "revenuePerShare": 0.138, "returnOnAssets": -0.51823, "returnOnEquity": -1.03991, "grossProfits": 10500000, "freeCashflow": -64799624, "operatingCashflow": -100165000, "revenueGrowth": 1.167, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -3.1412299, "financialCurrency": "USD", "symbol": "PRLD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "earningsTimestamp": 1762954200, "earningsTimestampStart": 1762954200, "earningsTimestampEnd": 1762954200, "earningsCallTimestampStart": 1762952400, "earningsCallTimestampEnd": 1762952400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.47, "epsForward": -1.145, "epsCurrentYear": -1.27, "priceEpsCurrentYear": -1.3464568, "fiftyDayAverageChange": 0.1695, "fiftyDayAverageChangePercent": 0.110029206, "twoHundredDayAverageChange": 0.6453451, "twoHundredDayAverageChangePercent": 0.6061542, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-09-25", "averageAnalystRating": "1.3 - Strong Buy", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1765583945, "regularMarketTime": 1765573201, "exchange": "NMS", "messageBoardId": "finmb_373775974", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Prelude Therapeutics Incorporat", "longName": "Prelude Therapeutics Incorporated", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1601040600000, "postMarketChangePercent": 0.58479476, "postMarketPrice": 1.72, "postMarketChange": 0.00999999, "regularMarketChange": 0.08, "regularMarketDayRange": "1.6021 - 1.72", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1375980, "fiftyTwoWeekLowChange": 1.1, "fiftyTwoWeekLowChangePercent": 1.8032787, "fiftyTwoWeekRange": "0.61 - 4.22", "fiftyTwoWeekHighChange": -2.5099998, "fiftyTwoWeekHighChangePercent": -0.5947867, "fiftyTwoWeekChangePercent": 81.91965, "cryptoTradeable": false, "regularMarketChangePercent": 4.90798, "regularMarketPrice": 1.71, "trailingPegRatio": null, "__fetch_time": "2025-12-13"}]